554 recruiting. 554 Phase 2, 80 Phase 1, 53 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 554 | Recruiting 554 |
| Phase 1 | 80 | Recruiting 80 |
| Phase 3 | 53 | Recruiting 53 |
Follow Mental Disorders: new trials by email Literature Review of Mental Disorders trials Research Report on Mental Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intranasal Oxytocin Intervention for Caregivers to Persons With Dementia Placebo, Oxytocin Intranasal Spray 12 International Unit (12IU), Oxytocin Intranasal Spray 24 International Unit (24IU) - Stress | Phase 2 | Recruiting | University of Nebraska | 32 | 2026-12-20 | 2026-11-02 |
| Effects of Ketones on Brain Energetics and Alcohol Consumption in Alcohol Use Disorder Kenetik, magnetic resonance imaging scan, Alcohol bar lab - Alcohol Use Disorder, Ketosis | Phase 2 / Phase 3 | Recruiting | University of Pennsylvania | 60 | 2026-12-01 | 2026-10-21 |
| A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial Neuronavigated robotic-enabled TMS, NRX-101, Sham TMS - Treatment Resistant Depression, Treatment Resistant Depression (TRD) | Phase 2 / Phase 3 | Recruiting | NeuroRx, Inc. | 240 | 2026-12-01 | 2026-10-21 |
| Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin Psilocybin, Cognitive Training - Alzheimer's Disease | Phase 2 | Recruiting | National Institute on Aging (NIA) | 200 | 2026-11-05 | 2026-11-02 |
| Cannabidiol as an Adjunct Treatment for Alcohol Withdrawal and Craving Cannabidiol (CBD), Placebo - Alcohol Use Disorder (AUD), Withdrawal From Addictive Substance; Detoxification | Phase 2 / Phase 3 | Recruiting | Johns Hopkins University | 105 | 2026-11-01 | 2026-10-02 |
| A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety CYB003, Placebo - Depression, Anxiety | Phase 2 | Recruiting | Ohio State University | 40 | 2026-11-01 | 2026-10-20 |
| Heart Rate Variability Biofeedback for Anxiety in Autistic Youth Lief Smart Patch - Autism Spectrum Disorder, Anxiety | Phase 2 | Recruiting | Massachusetts General Hospital | 50 | 2026-10-26 | 2026-10-16 |
| Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder Tirzepatide, Placebo (saline) - Methamphetamine Use Disorder | Phase 2 | Recruiting | University of Texas Southwestern Medical Center | 228 | 2026-10-23 | 2026-10-26 |
| Psilocybin AsSisted pSychotherapy for the treatmENt of Gambling disordER : a Pilot Study Psychotherapy assisted by high-dose psilocybin (25mg or 40mg where appropriate), Psychotherapy assisted by low-dose psilocybin (1 mg) - Gambling Disorder | Phase 2 | Recruiting | Nantes University Hospital | 30 | 2026-10-08 | 2026-10-16 |
| A Study of Cebranopadol for Opioid Withdrawal Symptoms in Adults With Chronic Pain Cebranopadol, Placebo - Chronic Pain, Pain | Phase 2 | Recruiting | Adneuris Therapeutics, Inc. | 45 | 2026-10-01 | 2026-10-23 |
| Hyperbaric Oxygen Therapy for Veterans With TBI and PCS: A Biomarker Study Hyperbaric Oxygen Therapy (HBOT) - Traumatic Brain Injury (TBI) Patients, Post Concussive Symptoms | Phase 2 | Recruiting | Summit Hyperbarics and Wellness | 34 | 2026-10-01 | 2026-09-30 |
| Sertraline Combined With Multi-Strain Probiotics for Adolescent Depression Sertraline - Major Depressive Disorder (MDD), Probiotic Intervention | Phase 2 | Recruiting | First Affiliated Hospital of Chongqing Medical University | 120 | 2026-10-01 | 2026-06-12 |
| Endocannabinoids in Reward Dronabinol, Placebo - Cannabis Use Disorder | Phase 2 | Recruiting | Medical University of South Carolina | 78 | 2026-10-01 | 2026-10-05 |
| A Study to Evaluate the Safety and Efficacy of ALKS 7290 as an Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder ALKS 7290 Dose, Placebo - Major Depressive Disorder (MDD) | Phase 2 | Recruiting | Alkermes, Inc. | 180 | 2026-10-01 | 2026-10-28 |
| TRIal of PPF3 vs. PlaCEbo in the TReatment of Children and AdolescenTs With NeurOdeveloPmental DisorderS PPF3, Placebo - Autism Disorder | Phase 2 | Recruiting | Holland Bloorview Kids Rehabilitation Hospital | 100 | 2026-10-01 | 2026-10-29 |
| Synaptic Mechanisms of Intermittent Theta Burst Stimulation for Major Depressive Disorder Sham iTBS, TMS, D-cycloserine - Major Depression, Healthy Participants | Phase 1 / Phase 2 | Recruiting | Mclean Hospital | 100 | 2026-10-01 | 2026-10-30 |
| Deep Sleep in Older Adults SleepSpaceRx CBT-I-IoT-AI, SleepEZ CBTi, Sleep Hygiene IoT - Insomnia, Insomnia Chronic | Phase 2 | Recruiting | Proactive Life Inc | 180 | 2026-09-30 | 2026-10-20 |
| SONATA Dose Duration LIFU for OCD ATTN201 - Low Intensity Focused Ultrasound - Obsessive - Compulsive Disorder | Phase 2 | Recruiting | University of Pennsylvania | 20 | 2026-09-15 | 2026-10-21 |
| HBOT Effects on First Responders' Cognition and Well-Being Hyperbaric Oxygen Therapy (HBOT) - Traumatic Brain Injury, PTSD - Post Traumatic Stress Disorder | Phase 2 | Recruiting | Summit Hyperbarics and Wellness | 54 | 2026-09-11 | 2026-10-01 |
| Focused Ultrasound for PTSD in Veterans Brainsonix Ultrasound Device - Posttraumatic Stress Disorder | Phase 2 | Recruiting | VA Office of Research and Development | 60 | 2026-09-09 | 2026-09-15 |
Showing 20 of 554. Sign in to see all of them.
Alzheimer Disease (74) · Cognitive Dysfunction (58) · Depressive Disorder, Major (57) · Depression (49) · Stress Disorders, Post-Traumatic (48) · Alcoholism (44) · Anxiety Disorders (36) · Opioid-Related Disorders (32) · Schizophrenia (29) · Autism Spectrum Disorder (26) · Dementia (26) · Marijuana Abuse (20) · Sleep Initiation and Maintenance Disorders (19) · Depressive Disorder, Treatment-Resistant (17)
Nervous System Diseases (173) · Neurocognitive Disorders (133) · Chemically-Induced Disorders (119) · Central Nervous System Diseases (117) · Brain Diseases (114) · Substance-Related Disorders (108) · Behavior (106) · Pathological Conditions, Signs and Symptoms (100) · Neurodegenerative Diseases (96) · Signs and Symptoms (78) · Mood Disorders (76) · Tauopathies (72) · Neurologic Manifestations (67) · Dementia (66)
Psilocybin (34) · Cannabidiol (17) · Ketamine (15) · N-Methyl-3,4-methylenedioxyamphetamine (11) · Sodium Chloride (10) · Tirzepatide (8) · Therapeutics (7) · semaglutide (7) · Cognitive Behavioral Therapy (6) · Dronabinol (6) · Ethanol (6) · Saline Solution (6) · suvorexant (6) · Acetylcysteine (5) · Buprenorphine (5)
Yale University (13) · Stanford University (12) · China Medical University Hospital (11) · Johns Hopkins University (11) · University of Pennsylvania (8) · VA Office of Research and Development (8) · Brigham and Women's Hospital (7) · Massachusetts General Hospital (7) · Mclean Hospital (6) · Ohio State University (6) · University of California, Los Angeles (6) · University of Colorado, Denver (6) · University of Maryland, Baltimore (6) · University of Minnesota (6) · AbbVie (5)
United States (351) · Canada (59) · China (25) · Spain (23) · France (20) · Australia (19) · Taiwan (19) · Italy (16) · Israel (15) · United Kingdom (15) · Germany (13) · South Korea (12) · Brazil (11) · Japan (11) · Netherlands (11)
Antonio Y. Hardan, MD (3) · Bernardino Clavo, MD, PhD (3) · Daniel S Pine, M.D. (3) · Ishrat Husain, MBBS, MD (3) · Avi Avital, PhD (2) · Brendan Lucey, MD (2) · Carlos A Zarate, M.D. (2) · Carolyn Rodriguez, MD, PhD (2) · Corinde Wiers, Ph.D. (2) · Elizabeth A Lawson, MD (2) · Emil Coccaro, M.D. (2) · Eric M McDade, DO (2)
PMID 33972795, PMID 42171126, PMID 15734224, PMID 19260079, PMID 20717121, PMID 21427067, PMID 21575276, PMID 23102757, PMID 23549581, PMID 24687190, PMID 24733808, PMID 24740528, PMID 25344944, PMID 25563446, PMID 25699252, PMID 25784600, PMID 26544668, PMID 27010975, PMID 27056608, PMID 27210031, PMID 27909164, PMID 28407726, PMID 29549516, PMID 29625429, PMID 29792726, PMID 30091969, PMID 30283029, PMID 30336704, PMID 30616705, PMID 30917760, PMID 30944474, PMID 30968800, PMID 31060042, PMID 31064595, PMID 31065731, PMID 31352029, PMID 31636488, PMID 31656217, PMID 31681040, PMID 31779159, PMID 31786934, PMID 31955915, PMID 32077442, PMID 32098487, PMID 32138938, PMID 32371500, PMID 32379556, PMID 32452462, PMID 32757505, PMID 32885244
2025 (14), 2023 (6), 2019 (3), P50HD109861 (3), R01DC017476 (2), U01AG059798 (2), 1DP5OD036172-01 (1), 1UG3DA062088-01 (1), 1UG3NS133515-01A1 (1), 5KL2TR002379 (1), 5KL2TR002379-08 (1), I01CX002372 (1), I01RX004287 (1), IK2CX002363-01A1 (1), IK2RX002938 (1)